- Home
- SLND vs DMAC Comparison
SLND vs DMAC Comparison
Compare SLND & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- DMAC
- Stock Information
- Founded
- SLND 1900
- DMAC 2000
- Country
- SLND United States
- DMAC United States
- Employees
- SLND N/A
- DMAC N/A
- Industry
- SLND Military/Government/Technical
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SLND Industrials
- DMAC Health Care
- Exchange
- SLND Nasdaq
- DMAC Nasdaq
- Market Cap
- SLND 175.8M
- DMAC 178.0M
- IPO Year
- SLND N/A
- DMAC N/A
- Fundamental
- Price
- SLND $4.49
- DMAC $3.76
- Analyst Decision
- SLND Strong Buy
- DMAC Strong Buy
- Analyst Count
- SLND 1
- DMAC 2
- Target Price
- SLND $5.00
- DMAC $8.00
- AVG Volume (30 Days)
- SLND 72.5K
- DMAC 307.4K
- Earning Date
- SLND 08-11-2025
- DMAC 08-06-2025
- Dividend Yield
- SLND N/A
- DMAC N/A
- EPS Growth
- SLND N/A
- DMAC N/A
- EPS
- SLND N/A
- DMAC N/A
- Revenue
- SLND $931,568,000.00
- DMAC N/A
- Revenue This Year
- SLND $3.76
- DMAC N/A
- Revenue Next Year
- SLND $1.08
- DMAC N/A
- P/E Ratio
- SLND N/A
- DMAC N/A
- Revenue Growth
- SLND N/A
- DMAC N/A
- 52 Week Low
- SLND $1.85
- DMAC $2.80
- 52 Week High
- SLND $4.67
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SLND 71.29
- DMAC 47.18
- Support Level
- SLND $3.66
- DMAC $3.48
- Resistance Level
- SLND $4.62
- DMAC $3.99
- Average True Range (ATR)
- SLND 0.26
- DMAC 0.32
- MACD
- SLND 0.05
- DMAC -0.00
- Stochastic Oscillator
- SLND 87.04
- DMAC 41.01
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.